Drug intelligence / Profile preview

elvitegravir

Development stage: Approved
Lead developer: Gilead Sciences
Modality: Small Molecules
Administration: Oral

Overview

Elvitegravir is an antiretroviral drug used in combination with other agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. It acts as an integrase strand transfer inhibitor (INSTI), blocking the HIV-1 integrase enzyme that is essential for viral replication. By inhibiting this enzyme, elvitegravir prevents the integration of viral DNA into the host genome, thereby halting propagation of HIV within the body. Elvitegravir was developed by Gilead Sciences and was originally licensed from Japan Tobacco[2][5]. It is indicated primarily for use in adults who have previously received antiretroviral therapy[8].

Brand names: GenvoyaStribildVitekta
Other names: elvitegravir

Targets

Integrase allosteric pocket (HIV)

Beyond the preview

Go deeper on elvitegravir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on elvitegravir.

Explore the full profile